Get the Stockscreener App
0.882
0.02%
0.0002
After Hours:
.91
0.028
+3.17%
Mira Pharmaceuticals Inc stock is traded at $0.882, with a volume of 26,317.
It is up +0.02% in the last 24 hours and down -12.67% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.8818
Open:
$0.88
24h Volume:
26,317
Relative Volume:
0.25
Market Cap:
$37.06M
Revenue:
-
Net Income/Loss:
$-31.37M
P/E Ratio:
-0.6134
EPS:
-1.438
Net Cash Flow:
$-4.23M
1W Performance:
-4.13%
1M Performance:
-12.67%
6M Performance:
-34.18%
1Y Performance:
-49.02%
1-Day Range:
$0.8698
$0.9498
1-Week Range:
$0.8301
$0.95
52-Week Range:
$0.8301
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.882 | 37.06M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,197.53 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.95 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.91 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.76 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.11 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:-0.046 - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Pharmaceuticals (MIRA) Holds Near Support with Modest Gains, Resistance at $0.97 in FocusStock Surge Alerts - dars.gov.et
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan
MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Pharmaceuticals Company Profile & Introduction - Moomoo
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et
What's going on with MIRA Pharma stock Tuesday? - MSN
MIRAMira Pharmaceuticals Inc Options - Finviz
MIRA Q3 2025 Earnings: Loss Narrows as EPS Surprises to the Upside, but Stock SlipsEarnings Revision Upgrade - dars.gov.et
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo
MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell Microcap Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com
MIRA Pharmaceuticals Inc. (MIRA) Rallies 11%: Approaching Key Resistance LevelEquity Put Call - dars.gov.et
Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView
K6S Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Flat at Open - Baystreet.ca
MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):